Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases

作     者：Giovanni Brandi Michela Venturi Stefania De Lorenzo Francesca Garuti Giorgio Frega Andrea Palloni Ingrid Garajovà Francesca Abbati Gioconda Saccoccio Rita Golfieri Maria Abbondanza Pantaleo Maria Aurelia Barbera 

作者机构：Department of ExperimentalDiagnostic and Specialty MedicineSt.Orsola-Malpighi HospitalHaematological and Oncological InstituteUniversity of Bologna9 Massarenti street40138 BolognaItaly Department of Medical and Surgical SciencesSt.Orsola-Malpighi HospitalUniversity of Bologna40138 BolognaItaly Department of MedicineBologna Health Authority40139 BolognaItaly Department of Digestive Diseases and Internal MedicineSt.Orsola-Malpighi HospitalUniversity of Bologna40138 BolognaItaly 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2018年第38卷第1期

页      面：429-435页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Hepatocellular carcinoma Capecitabine Metronomic capecitabine Complete response Sorafenib 

摘      要：Background:Hepatocellular carcinoma(HCC)is one of the most frequent causes of cancer-related ***,a multitarget angiogenesis inhibitor,is an approved frontline treatment for advanced HCC in Western countries,although a complete response(CR)to treatment is infrequently ***,an oral fluoropyrimidine,has been shown to be effect in both treatment-naïve patients and those previously treated with *** date,how-ever,only one case of sustained CR to metronomic capecitabine has been *** presentation:We describe three cases of advanced HCC treated with metronomic capecitabine where a CR was *** the first case,capecitabine was administered as first line therapy;in the second case,capecitabine was used after intolerance to sorafenib;while in the third case,capecitabine was administered after sorafenib ***:Capecitabine is a potentially important treatment option for patients with advanced HCC and may even represent a cure in certain cases.